Lilly’s Olumiant (baricitinib) Receives CHMP’s Positive Opinion for Moderate to Severe Atopic Dermatitis

 Lilly’s Olumiant (baricitinib) Receives CHMP’s Positive Opinion for Moderate to Severe Atopic Dermatitis

Lilly’s Olumiant (baricitinib) Receives CHMP’s Positive Opinion for Moderate to Severe Atopic Dermatitis

Shots:

  • The positive opinion is based on P-III BREEZE-AD program including BREEZE-AD1 & BREEZE-AD2 studies assessing baricitinib as monothx. in mod. to sev. AD patients
  • The CHMP’s recommendation also involves a BREEZE-AD4 study assessing baricitinib + topical corticosteroids in patients with mod. to sev. AD who have failed or who are intolerant to or have contraindications to cyclosporine and BREEZE-AD7 study assessing baricitinib + topical corticosteroids in patients with mod. to sev. AD
  • The positive opinion marks the first step toward EU approval for baricitinib for patients with AD. If approved, the therapy would become the first JAK inhibitor for AD with expected EC’s decision in the next 2mos.

Click here ­to­ read full press release/ article | Ref: Eli Lilly | Image: Bilaterals

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post